• Home Sophia Zoungas.

Sophia Zoungas.

Matthews, B.M., Ph.D., Carl E. Mogensen, M.D., Ph.D., Vlado Perkovic, M.D., Ph.D., Neil Poulter, M.D., F.Med.Sci., Anthony Rodgers, M.D., Ph.D., Bryan Williams, M.D., Ph.D., Stephen MacMahon, D.Sc., Ph.D., Anushka Patel, M.D., Ph.D., and Mark Woodward, Ph.D. For the ADVANCE-ON Collaborative Group: Follow-up of Blood-Pressure Decreasing and Glucose Control in Type 2 Diabetes Post-trial follow-up studies involving individuals with diabetes have previously shown long-term beneficial ramifications of earlier periods of intensive glucose control, however, not blood-pressure lowering, on a range of outcomes, including mortality and macrovascular events.1-3 The Epidemiology of Diabetes Interventions and Complications research, an extension of the Diabetes Control and Complications Trial involving youthful patients with type 1 diabetes no history of cardiovascular disease, hypertension, or hypercholesterolemia, showed a lesser risk of macrovascular events, in addition to a sustained benefit regarding microvascular complications, beyond the time of intensive glucose control.1 The post-intervention follow-up of the uk Prospective Diabetes Study also showed long-term beneficial effects of intensive glucose control in sufferers with newly diagnosed type 2 diabetes.2 Among patients formerly assigned to intensive therapy as compared with conventional therapy, the reduced risk of microvascular events was preserved, and previously non-significant estimates of the effect of intensive therapy on the finish points of death and myocardial infarction became significant with prolonged follow-up.2 In contrast, no long-term benefits had been detected with improved blood-pressure control in the UKPDS.3 The Actions in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial assessed the consequences of routine blood-pressure reducing and intensive glucose control in a wide cross section of individuals with type 2 diabetes.4,5 Routine administration of a single-pill combination of perindopril and indapamide was connected with a decrease in the risk of the principal composite end point of key macrovascular or microvascular events.Accordingly, we very much look forward to the continuing advancement of ALN-TTR02, including the start of the Phase I clinical trial in healthful volunteers in the 1st half of this year and data in the 3rd quarter. We also be prepared to initiate a Stage II study with ALN-TTR02 in familial amyloidotic polyneuropathy, or FAP, patients in the second half of the year with the beginning of pivotal trials with ALN-TTR02 in 2013.’ Related StoriesUnderstanding how schizophrenia affects workings of the brainApoE4-carrying men with Alzheimer's disease vulnerable to mind bleedsPresence of connexin proteins suppresses primary tumor growthATTR can be an autosomal dominant inherited disease caused by mutations in the TTR gene, which is expressed predominantly in the liver and outcomes in the accumulation of pathogenic deposits of mutant and wild-type TTR protein in multiple extra-hepatic cells, including the peripheral nervous program, gastrointestinal tract, and center.